In a groundbreaking development in the field of biotechnology, Shanghai CirCode Biomed Co. Ltd. has announced that its innovative drug, HM2002, has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA).
This marks a significant milestone not only for the company but also for the medical community as HM2002 becomes the first circular RNA drug to be administered to patients.
This pioneering therapy is set to tackle ischemic heart disease, a condition that has increasingly become a leading cause of mortality worldwide.
The announcement, made on May 30, 2025, comes on the heels of the drug’s initial patient administration in September 2024 during an investigator-initiated trial (IIT) at Ruijin Hospital.
The rapid pace of development—from the drug’s conceptual stage to IND approval—has been facilitated by CirCode’s proprietary circular RNA platform and cutting-edge artificial intelligence tools.
This innovation has allowed the company to navigate regulatory pathways effectively, culminating in approvals from both the FDA and China’s National Medical Products Administration (NMPA) in a matter of months.
Ischemic heart disease poses a growing challenge as the global population ages, with its incidence continuing to rise.
Current treatment regimens have been criticized for their limited effectiveness in enhancing myocardial microcirculation and promoting angiogenesis, which are crucial for improving patient outcomes. With the grim statistics surrounding heart disease, the medical field is in urgent need of next-generation therapies that can genuinely enhance patients’ quality of life.
HM2002 aims to fill this gap.
The drug employs circular RNA technology to achieve a stable, low-immunogenic expression of vascular endothelial growth factor (VEGF) in the myocardium.
VEGF is known for its role in promoting blood vessel formation, and the ability to deliver it safely and effectively could revolutionize treatment for ischemic heart disease.
In preclinical studies, HM2002 has shown promising safety and efficacy, with all subjects in the initial human trial reporting significant improvements in cardiac function and no adverse drug-related events.
Dr. Chenxiang Tang, CEO of CirCode, highlighted the innovative approach of HM2002, stating, “To promote angiogenesis and relieve ischemia through VEGF overexpression is a well-tested solution, but there is a tremendous challenge to achieve an efficient, persistent, and controllable expression of VEGF in vivo.”
He emphasized that the unique properties of circular RNA allow for a single dose of HM2002 to provide a timely expression of VEGF, optimizing the conditions for effective angiogenesis while mitigating safety risks.
The IND clearances from both the FDA and NMPA serve as strong endorsements of CirCode’s innovation and position in the circular RNA therapeutic landscape.
Dr. Yun Yang, co-founder and chairman of CirCode, expressed pride in the rapid advancement of HM2002, which underscores the company’s commitment to addressing unmet medical needs.
He noted that CirCode has established a robust pipeline that spans various therapeutic areas, including cardiovascular diseases, infectious diseases, autoimmune disorders, and oncology.
Many of these projects are expected to enter clinical trials within the next year, reflecting the company’s ambition to push the boundaries of circular RNA therapy.
As the healthcare industry grapples with the complexities of treating chronic diseases, the introduction of HM2002 is not just a beacon of hope for patients suffering from ischemic heart disease; it also signifies a paradigm shift in how therapies can be developed and deployed.
With the backing of leading investors and a solid patent portfolio, CirCode is well-positioned to lead the charge in circular RNA therapeutics.
In an age where innovation is key to medical advancement, HM2002 represents a monumental step forward.
As the world continues to face the challenges of an aging population and the diseases that accompany it, the successful application of circular RNA technology could pave the way for new treatment modalities, ultimately transforming the landscape of modern medicine.
The journey of HM2002 is just beginning, but its potential impact on patient care could be profound, ushering in a new era of therapeutic possibilities.
The Swiss pharmaceutical giant partners with Alteogen to leverage advanced enzyme technology for the transition of intravenous biologics to subcutaneous delivery.
New research reveals that when dietary fiber is scarce, gut bacteria may consume the body’s own protective lining, highlighting a critical role for indigestible plant proteins.
Forensic scientists are refining techniques to turn bacterial traces into reliable evidence, aiming to bridge the gap in investigations where traditional DNA fails.
